Full Text
Full Text PDF
Abstract
Abstract Background/Aims: Tumor necrosis factor-α (TNF-α) inhibitors and ustekunimab are widely used in autoimmune diseases. It is known that these biological agents cause the reactivation of hepatitis B virus (HBV). There is no standardized strategy to prevent the reactivation in patients with evidence of a previous HBV infection. In our study, anti-HBc IgG-positive patients who received a biological agent were evaluated in terms of HBV reactivation. Materials and Methods: Patients who were followed up for the use of biological agents in our clinic were evaluated retrospectively. Patients with isolated anti-HBc IgG positivity were included in the study. The HBV reactivation data were recorded from the patients’ files retrospectively. Results: Two hundred and seventy-eight patients who received biological treatment were evaluated. Twenty-nine patients with isolated anti-HBc IgG positivity or resolved HBV infection were included in the study. The HBV reactivation was seen in 5 patients (17.2%). Of these patients, 3 were using adalimumab, 1 infliximab, and 1 ustekunimab. It was controlled by antiviral therapy that was started in the early period. Conclusion: Drugs that block TNF-α and ustekunimab cause an increase in viral replication. In literature, the HBV reactivation rate was approximately 1% in HBsAg-negative, anti-HBC IgG-positive cases, whereas it was found to be as high as 17.2% in our study. Patients receiving the immunomodulator therapy should be evaluated for HBV serology before treatment and carefully monitored for HBV reactivation during and after treatment. Cite this article as: Solay AH, Acar A, Eser F, et al. Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity. Turk J Gastroenterol 2018; 29: 561-5.
Most read articles by the same author(s)
- Ramazan Idilman, Nurcan Baykam, Sabahattin Kaymakoğlu, Fehmi Tabak, Halil İ. Bahçecioğlu, Ahmet Bektaş, Cemal Bulut, Fulya Günşar, Dilara İnan, Hayat K. Karaosmanoğlu, Zeki Karasu, Ferit Kuşçu, Birgül Mete, Ömer Özbakır, Osman C. Özdoğan, Mehmet Parlak, Fatma Sırmatel, Ömer Topalak, Belkis Ünsal, and Viral Hepatisis Guideline Study Group, Turkey 2017 Clinical Practice Guidelines on recommendations for screning diagnosing and managing hepatitis C virus , Turkish Journal of Gastroenterology: Vol. 28 No. 2 (2017): Turkish Journal of Gastroenterology
- Sibel Yıldız Kaya, Behice Kurtaran, Nefise Öztoprak Çuvalcı, Yusuf Önlen, Mehmet Reşat Ceylan, Esra Zerdali, Nagehan Didem Sarı, Ahsen Öncül, Nurettin Erben, Ayse Batirel, Dilara İnan, Süheyla Kömür, Figen Sarıgül Yıldırım, Hasibullah Yaqoobi, Ferit Kuscu, Rahmet Guner, Fehmi Tabak, Hep-C Türkiye Study Group, Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3 , Turkish Journal of Gastroenterology: Vol. 37 No. 1 (2026): Turkish Journal of Gastroenterology
- Neşe Demirtürk, Bilgehan Aygen, İlhami Çelik, Reşit Mıstık, Sıla Akhan, Şener Barut, Onur Ural, Ayşe Batırel, Funda Şimşek, Gülden Ersöz, Dilara İnan, Sami Kınıklı, Nesrin Türker, Hüseyin Bilgin, Yunus Gürbüz, Necla Tülek, Hüseyin Tarakçı, Orhan Yıldız, Emine Türkoğlu, Deniz Kamalak Güzel, Sümeyra Şimşek, Nazan Tuna, Nazlım Aktuğ Demir, Atahan Çağatay, Rıza Aytaç Çetinkaya, Faruk Karakeçili, İsmail Necati Hakyemez, Günay Tuncer Ertem, Bahar Örmen, Pınar Korkmaz, Uluhan Yıldız, Ziya Kuruüzüm, Alper Şener, Selcan Arslan Özel, Sinan Öztürk, Kaya Suer, Mustafa Kemal Çelen, Petek Konya, Ali Asan, Neşe Saltoğlu, Nurhan Doğan, Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective? , Turkish Journal of Gastroenterology: Vol. 32 No. 2 (2021): Turkish Journal of Gastroenterology
- İftihar Köksal, Gürdal Yılmaz, Mehmet Parlak, Tuna Demirdal, Sami Kınıklı, Mehmet Candan, Ali Kaya, Sıla Akhan, Özcan Aydoğdu, Hüseyin Turgut, Yunus Gürbüz, Özgür Dağlı, Ahmet Ali Gökal, Rahmet Güner, Ziya Kuruüzüm, Hüseyin Tarakçı, Nuri Beslen, Seda Erdoğan, Fatih Özdener, The Chronic Hepatitis C Study Group, Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study , Turkish Journal of Gastroenterology: Vol. 29 No. 4 (2018): Turkish Journal of Gastroenterology
- Ali Acar, Hamit Yaşar Ellidağ, Kadir Balaban, Serkan Öcal, Arif Aslaner, Tuğrul Çakır, Investigation of Serum Human Epididymitis Protein 4 Level in Rats with Experimental Acute Pancreatitis , Turkish Journal of Gastroenterology: Vol. 34 No. 6 (2023): Turkish Journal of Gastroenterology
Article Info
Published In
Journal
Turkish Journal of Gastroenterology
Volume / Issue
Volume 29 · Issue 5
Pages
561-565
History
Published Online
September 15, 2018
Copyright
Copyright (c) 2018 Aslı Haykır Solay, Ali Acar, Fatma Eser, Ferit Kuşcu, Emin Ediz Tütüncü, Gülnur Kul, Gönül Çiçek Şentürk, Yunus Gürbüz
Affiliations
Aslı Haykır Solay
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Ali Acar
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Fatma Eser
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Ferit Kuşcu
Department of Infection Disease and Clinical Microbiology, Çukurova University School of Medicine, Adana, Turkey
Emin Ediz Tütüncü
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Gülnur Kul
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Gönül Çiçek Şentürk
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Yunus Gürbüz
Department of Infectious Diseaes, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Cite this Article
Haykır Solay, A., Acar, A., Eser, F., Kuşcu, F., Tütüncü, E. E., Kul, G., … Gürbüz, Y. (2018). Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity. Turkish Journal of Gastroenterology, 29(5), 561–565. https://doi.org/10.5152/tjg.2018.18032
Outlines